The challenge of protecting the perinatal brain against hypoxic ischaemic injury – hasten slowly
Suzanne L. Miller,D. Walker
DOI: https://doi.org/10.1113/jphysiol.2013.268888
2014-02-01
Journal of Physiology
Abstract:Hypoxic ischaemic episodes in utero are a principal cause of hypoxic ischaemic encephalopathy (HIE) in the newborn, and in turn HIE results in high rates of permanent disability and cerebral palsy. Accordingly, much clinical interest and research is aimed at identifying those fetuses and neonates at risk of perinatal hypoxia– ischaemia, and reducing the progression of brain injury. To be effective any neuroprotective strategy must correct the pathophysiology that causes brain injury. This is particularly challenging in neonatal HIE because the pathways that lead to cellular degeneration in the brain are likely to be multifactorial, involving glutamate-mediated excitotoxicity, oxidative stress, inflammation and cell-death signalling pathways (Ferriero, 2004). The recognition that hypothermia commenced within 6 h of birth reduces neonatal brain injury following hypoxia–ischaemia in term infants (Edwards et al. 2010) shows that the pathogenic processes leading to injury can be interrupted, providing a strong impetus to examine further options targeting the pathways likely to be involved in injury to the young brain. One such neuroprotective therapy is allopurinol. Allopurinol is an inhibitor to xanthine oxidase, and its administration reduces oxygen free radical production by preventing the conversion of hypoxanthine to uric acid. Experimentally, maternal allopurinol administration during pregnancy prevents neuronal loss in term fetal hypoxia–ischaemia (Kaandorp et al. 2014), and it is the antioxidant properties of allopurinol postulated to underlie its neuroprotective actions that have been examined in small and large animal experimental studies (reviewed in Miller et al. 2012).
For the past several years, the ALLO-Trial has been administering allopurinol to pregnant women at term where the fetus is suspected of having acute severe intrauterine hypoxia (Kaandorp et al. 2010). The ALLO-Trial aims to reduce encephalopathy after birth by muting the burden of early oxidative stress in the fetal brain during or after hypoxia, thereby reducing oxidative stress-induced brain injury. In doing so, allopurinol alters fetal oxidative balance. This has important implications, with Herrera et al. (2012) recently showing that xanthine oxidase plays a fundamental role in fetal basal cardiovascular function. In this issue of The Journal of Physiology, Kane et al. (2014) significantly advance this story, presenting results from a basic science ovine fetal study to elucidate the roles and the interactions between xanthine oxidase, generation of reactive oxygen species, and nitric oxide, shown to play a principal role in basal peripheral vasoconstrictor tone in the fetus and the cardiovascular reflex response of the fetus to hypoxic stimuli. In this study, Kane et al. demonstrate that maternal allopurinol administration significantly attenuates the fetal vasoconstrictor response to hypoxia, an effect of allopurinol that is mediated by increased availability of nitric oxide.
This finding raises important issues concerning the use of any treatment given prophylactically to protect the fetal brain. The late gestation fetus has robust cardiovascular defences to hypoxia designed to maintain oxygen supply to the heart and brain, involving peripheral vasoconstriction triggered by chemosensory reflexes and adrenal release of catecholamines (Giussani et al. 1993). This clever systemic response serves to maintain oxygen delivery to the heart and brain while hypoxic conditions persist, and it is this important peripheral vasoconstriction that the current study shows is reduced when maternal allopurinol is administered. It is therefore entirely appropriate that Kane et al. query whether allopurinol-induced mediation of the cardiovascular response to fetal hypoxia may offset some of its neuroprotective benefits.
Crucially, this study prompts us to evaluate the problems that may arise when treating one pathway implicated in hypoxia-mediated cell damage, in this case by dampening the potential for oxidative stress-induced brain injury, at the expense of other adaptive responses. In the setting of clinical trials now underway that are treating hypoxic fetuses with allopurinol, or indeed other antioxidants that mediate vascular tone, it is prudent to ask what are the consequences, both immediate and long-term, of altering the fetus's own defence to hypoxic challenge. This defence is critical in cases of fetal hypoxia. Additionally, what are the effects of allopurinol in non-hypoxic fetuses, who are not at risk of hypoxic ischaemic brain injury? Identifying the hypoxic fetus remains a major problem in obstetric practice. This is almost always done indirectly, for example from an abnormal heart rate or absence of fetal movements, and it would be understandable to find that allopurinol was being used prospectively in pregnancies where a fetus might be hypoxic, or was in danger of becoming hypoxic. In these cases, for the reasons outlined by Kane et al., the fetus could be prevented from making full adaptive responses to acute hypoxia should it arise at birth. Furthermore, it is not yet known if antenatal allopurinol affects the major transformation of the circulation at birth, when pulmonary blood flow increases and the placental circulation is lost.
A final reason for recommending caution in implementing antenatal allopurinol therapy at this point is that allopurinol may well be given in pregnancies when the fetus has other co-morbidities, such as chorioamnionitis, poor placental function, or growth restriction. In the context of allopurinol use in pregnancy, the present paper should be regarded as an important first step, with other major obstetric interactions yet to be evaluated (e.g. chronic, rather than acute, fetal hypoxia; hypoglycaemia; growth restriction). In addition, while the large multicentre randomized controlled trial on maternal treatment with allopurinol now running in the Netherlands will provide data on neonatal outcomes, this trial will not provide information on longer-term cardiovascular and neurological outcomes into childhood and adult life for many years to come. Further experimental studies in animals with short life spans should be evaluated: these might identify untoward consequences, or conversely ease concerns about adverse outcomes at stages of life equivalent to childhood and adulthood. Hence, experiments should progress to assess the overall utility of the use of allopurinol in pregnancy and, keeping the fetus in mind, it is clearly important to hasten slowly.